Active Ingredient History

  • Now
Samatasvir (IDX-719) is an experimental drug for the treatment of hepatitis C. It was originally developed by Idenix, and development has been continued by Merck & Co. following their acquisition of Idenix. Samatasvir has shown good results in Phase II trials.   Wikipedia

  • SMILES: COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1c2nc3cc(ccc3[nH]2)c4csc5c(csc45)c6ccc(cc6)c7c[nH]c(n7)[C@@H]8CCCN8C(=O)[C@H](NC(=O)OC)c9ccccc9
  • Mol. Mass: 885.08
  • ALogP: 9.37
  • ChEMBL Molecule:
More Chemistry
idx18719 | idx719 | samatasvir


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue